Redeye comments on the strong initial news flow around the launch of the new Carbonhand.
Analyst Group has entered into an agreement with Brain+ on commissioned research, including Equity R...
Redeye leaves a short comment following yesterday's news that a permanent CEO will take office in Ja...
Sherlock going strong with HC seeing seq. improvement Elevated RUB weighing on EBIT in 2022e and 2...
Q3 results due Thursday, 27 October We expect strong orders and sales but weak profits ’21-‘24e sa...
Q3e: sales up 23% y-o-y but margins remain pressured We expect 2023e to show improvements Small p...
Redeye updates its estimates ahead of the Q3 report (due 11 November).
On the 6th of October 2022, Fluicell (“Fluicell” or the “company”) announced that the company has re...
Guidance downgraded as large customer refuses to pay Focus on cash and liquidity intensified Scena...
Redeye updates its estimates for the Q2 report due to three announced acquisitions during the quarte...
Redeye thinks the large order from Trafikverket confirms Sensys Gatso’s almost impenetrable market p...
Redeye thinks yesterday’s deal between Seeing Machines and Magna will grant Seeing Machines a certai...
Audientes A/S is a Danish technology company specializing in smart, self-fitting and affordable hear...
Kvartalsestimat I denna analysuppdatering väljer vi att för första gången publicera estimat på kvart...
Enligt förväntan Ur ett finansiellt perspektiv stack inte rapporten ut åt något håll.
Redeye comments on Ultimovacs reporting a three-year survival OS rate of some 71% for cohort 1 of it...
Redeye is encouraged to learn that Vicore’s digital therapy “Almee” reduced anxiety by almost 50% in...
Financing options being explored Directed share issue of SEK 23.
Impressive transformation between 2018 and 2022 Increased focus on growth driven by digitalisation ...
We forecast Q3 sales and EBIT down 16-80% y-o-y Strong USD weighs on GM – weak consumer hits top li...
